Resbiotic Spins Out Pharmaceutical Subsidiary Alveolus Bio, Raises $4.5M Seed Funding And Launches First Consumer Health Product
Resbiotic Spins Out Pharmaceutical Subsidiary Alveolus Bio, Raises $4.5M Seed Funding And Launches First Consumer Health Product
10/26/21, 4:36 PM
Location
birminghamMoney raised
$4.5 million
Round Type
seed
Birmingham, Alabama-based biotech startup ResBiotic today announced the spin-out of its drug development arm, Alveolus Bio, and the launch of its first consumer health product, resB® Lung Support. With $4.5M in seed funding, ResBiotic and Alveolus Bio are poised to transform the respiratory care landscape and chart new frontiers for microbiome science.
Company Info
Location
birmingham, alabama, united states
Additional Info
ResBiotic is the world's first respiratory probiotics company pioneering science-backed supplements for lung health. Founded and managed by physician scientists, the company is the culmination of decades of research at the intersection of respiratory health and microbiome science. ResBiotic's first product, resB® Lung Support, is a dietary supplement that targets the gut-lung axis. To learn more visit www.resbiotic.com.
SOURCE ResBiotic